APRI (Aprinoia Therapeutics) EBITDA Margin %: -50,540.00% (As of Dec. 2023)


What is Aprinoia Therapeutics EBITDA Margin %?

Aprinoia Therapeutics APRI EBITDA Margin % is -50,540.00% as of Dec. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aprinoia Therapeutics's EBITDA for the six months ended in Dec. 2023 was $-17.69 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Therefore, Aprinoia Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -50,540.00%.

Aprinoia Therapeutics  (NAS:APRI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aprinoia Therapeutics EBITDA Margin % Related Terms

Aprinoia Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EBITDA Margin % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EBITDA Margin %
-4,164.91 -7,031.47 -254.65

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % 0.00 -4,567.80 -14,372.73 -59.83 -50,540.00

APRI vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's EBITDA Margin % falls into.


Aprinoia Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-23.094/9.069
=-254.65 %

Aprinoia Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-17.689/0.035
=-50,540.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -50,540.00% mean?
Aprinoia Therapeutics (APRI) has a EBITDA Margin % of -50,540.00% as of Dec. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' EBITDA Margin % too high?
Aprinoia Therapeutics' current EBITDA Margin % is -50,540.00%.
How does Aprinoia Therapeutics' EBITDA Margin % compare to ?
Aprinoia Therapeutics' EBITDA Margin % of -50,540.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current EBITDA Margin % is -50,540.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current EBITDA Margin % of -50,540.00%. The current EBITDA Margin % is -50,540.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current EBITDA Margin % is -50,540.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.